Выход
Вход/Login
 
E-mail
Пароль/Password
Забыли пароль?
Введите E-mail и жмите тут. Пароль будет выслан на указанный адрес
Войти (LogIn)

 

Если вы первый раз здесь, то зарегистрируйтесь

Регистрация/Sign Up
Полное имя (Ф.И.О.)/Name
E-mail
Телефон/Phone
Зарегистрироваться,
на ваш E-mail будет выслан временный пароль

 

Медицинская литература. Новинки


 

 

 

 

 
вce журналы << Анналы хирургической гепатологии << 2018 год << №2 <<
стр.11
отметить
статью

Роль радиочастотной термодеструкции в современной стратегии лечения больных злокачественными опухолями печени. Обзор литературы

Долгушин Б. И., Косырев В. Ю., Виршке Э. Р., Шолохов В. Н., Мартынков Д. В.
Купить файл публикации  79 руб. Купить все файлы этого журнала/книги  199 руб. Купить все журналы (файлы) за 2018 год  799 руб.
Долгушин Борис Иванович - доктор мед. наук, академик РАН, профессор, директор НИИ КиЭР ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, 115478, г. Москва, Каширское шоссе, д. 23, Российская Федерация
Косырев Владислав Юрьевич - доктор мед. наук, ведущий научный сотрудник лаборатории интервенционной радиологии НИИ КиЭР ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России; ФГАОУВО Первый МГМУ имени И.М. Сеченова Минздрава России, vkosirev@mail.ru, 115478, г. Москва, Каширское шоссе, д. 23, Российская Федерация
Виршке Эдуард Рейнгольдович - доктор мед. наук, заведующий лабораторией интервенционной радиологии НИИ КиЭР ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, 115478, г. Москва, Каширское шоссе, д. 23, Российская Федерация
Шолохов Владимир Николаевич - доктор мед. наук, профессор, ведущий научный сотрудник отделения ультразвуковой диагностики НИИ КиЭР ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, 115478, г. Москва, Каширское шоссе, д. 23, Российская Федерация
Мартынков Дмитрий Владимирович - научный сотрудник лаборатории интервенционной радиологии НИИ КиЭР ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, ФГБУ “НМИЦ онкологии им. Н.Н. Блохина” Минздрава России, 115478, г. Москва, Каширское шоссе, д. 23, Российская Федерация

Радиочастотная термодеструкция (термоабляция) остается одним из наиболее востребованных методов локального разрушения опухолей печени. Накоплен многолетний мировой опыт применения в онкологии, опубликовано множество исследований, и практические вопросы редко становятся предметом дискуссий. Вместе с тем все еще остаются стратегические вопросы: когда, кому, в каких ситуациях? По сути, признавая эффективность воздействия, специалисты не всегда уверены, при каких обстоятельствах потенциал радиочастотной термодеструкции будет реализован максимально. В обзоре литературы обобщен мировой опыт применения термоабляции при злокачественных опухолях печени. Сделана попытка выделить ключевые позиции при определении стратегии лечения с применением технологии. Безусловный приоритет в выработке оптимального лечения больных злокачественными опухолями печени имеет междисциплинарная кооперация.

Ключевые слова:
печень, злокачественное новообразование, метастазы, радиочастотная термодеструкция, абляция, liver, malignancy, metastases, radiofrequency thermodestruction, ablation

Литература:
1.Lahat E., Eshkenazy R., Zendel A., Zakai B.B., Maor M., Dreznik Y., Ariche A. Complications after percutaneous ablation of liver tumors: asystematic review. Hepatobiliary Surg. Nutr. 2014; 3 (5): 317-323. DOI: 10.3978/j.issn.2304-3881.2014.09.07.
2.Hinshaw J.L., Lubner M.G., Ziemlewicz T.J., Lee F.T. Jr., Brace C.L. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation - what should you use and why? Radiographics. 2014; 34 (5): 1344-1362. DOI: 10.1016/j.rcl.2015.05.012.
3.Ryan M.J., Willatt J., Majdalany B.S. Ablation techniques for primary and metastatic liver tumors. World J. Hepatol. 2016; 8 (3): 191-199. DOI: 10.4254/wjh.v8.i3.191.
4.Salati U., Barry A., Chou F.Y., Ma R., Liu D.M. State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. Future Oncol. 2017; 13 (16): 1437-1448. DOI: 10.2217/fon-2017-0061.
5.Van der Sluis F.J-F., Bosch J.L., Terkivatan T., de Man R.A., Ijzermans J.N., Hunink M.G. Hepatocellular adenoma: Cost effectiveness of different treatment strategies. Radiology. 2009; 252 (3): 737-746. DOI: 10.1148/radiol.2523082219.
6.Beer E., Kelly H.A., Ward G.E. Discussion of advances in surgery. Arch. Phys. Ther. X-Ray. Radium. 1931; 12: 471-472.
7.Beer E. Removal of neoplasms of the urinary bladder: a new method employing high frequency (Oudin) currents through a cauterizing cystoscope. JAMA. 1910; 54: 1768-1769.
8.Косырев В.Ю. Радиочастотная термоаблация в комбинированном лечении злокачественных опухолей печени (показания, методология, результаты лечения): дисс. ... д-ра мед. наук. М., 2011. 184 с.
9.Poon R.T., Ng K.K., Lam C.M., Ai V., Yuen J., Fan S.T. Radiofrequency ablation for subcapsular hepatocellularcarcinoma. Ann. Surg. Oncol. 2004; 11 (3): 281-289.
10.Wissniowski T.T., Hänsler J., Neureiter D., Frieser M., Schaber S., Esslinger B., Voll R., Strobel D., Hahn E.G., Schuppan D. Activation of tumor-specific T-lymphocytes by radiofrequency ablation of the VX2 hepatoma in rabbits. Cancer Res. 2003; 63 (19): 6496-6500.
11.Zerbini A., Pilli M., Penna A., Pelosi G., Schianchi C., Molinari A., Schivazappa S., Zibera C., Fagnoni F.F., Ferrari C., Missale G. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006; 66 (2): 1139-1146.
12.Shi L., Chen L., Wu C., Zhu Y., Xu B., Zheng X., Sun M., Wen W., Dai X., Yang M., Lv Q., Lu B., Jiang J. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin. Cancer Res. 2016; 22 (5): 1173-1184. DOI: 10.1158/1078-0432.CCR-15-1352.
13.Gish R.G., Lencioni R., Di Bisceglie A.M., Raoul J.L., Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Gastroenterol. Hepatol. 2012; 6 (2): 173-185. DOI: 10.1586/egh.11.105.
14.Jia-Yan Ni. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepato cellular carcinoma. World J. Gastroenterol. 2013; 19 (24): 3872-3882. DOI: 10.3748/wjg.v19.i24.3872.
15.Peng Z.W., Zhang Y.J., Chen M.S., Xu L., Liang H.H., Lin X.J., Guo R.P., Zhang Y.Q., Lau W.Y. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J. Clin. Oncol. 2013; 31 (4): 426-432. DOI: 10.1200/JCO.2012.42.9936.
16.Ding H., Su M., Zhu C., Wang L., Zheng Q., Wan Y. CT-guided versus laparoscopic radiofrequency ablation in recurrent small hepatocellular carcinoma against the diaphragmatic dome. Sci. Rep. 2017; 7: 44583. DOI: 10.1038/srep44583.
17.Eisele R.M., Neumann U., Neuhaus P., Schumacher G. Open surgical is superior to percutaneous access for radiofrequency ablation of hepatic metastases. World J. Surg. 2009; 33 (4): 804-811. DOI: 10.1007/s00268-008-9905-1.
18.Duhwan Yun D., Kim S., Son I., Chun K. Comparative analysis of laparoscopic versus open surgical radiofrequency ablation for malignant liver tumors. Korean J. Hepatobiliary Pancreat. Surg. 2014; 18 (4): 122-128. DOI: 10.14701/kjhbps.2014.18.4.122.
19.Rossi P., Manzelli A., Petrou A., Bramis K., Anselmo A., Iaria G., Toti L., Tommaso T.M., Berlanda M., Tisone G. RFA assisted liver resection combined with hanging manoeuvre: The alternative option for safe and bloodless major hepatectomy. Hellenic J. Surg. 2011; 83 (6): 347-351. DOI: 10.1007/s13126-011-0061-y.
20.Reccia I., Sodergren M.H., Jayant K., Kurz E., Carneiro A., Spalding D., Pai M., Jiao L., Habib N. The journey of radiofrequency-assisted liver resection. Surg. Oncol. 2018; pii: S0960-7404(17)30391-2. DOI: 10.1016/j.suronc.2018.01.004.
21.Fioole B., Jansen M.C., van Duijnhoven F.H., van Hillegersberg R., van Gulik T.M., Borel Rinkes I.H. Combining partial liver resection and local ablation of liver tumours: a preliminary Dutch experience. World J. Surg. Oncol. 2006; 4: 46.
22.Xu L.L., Zhang M., Yi P.S., Zheng X.B., Feng L., Lan C., Tang J.W., Ren S.S., Xu M.Q. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2017; 37 (6): 974-980. DOI: 10.1007/s11596-017-1836-3.
23.Hatanaka T., Kakizaki S., Yuhei S., Takeuchi S., Shimada Y., Takizawa D., Katakai K., Sato K., Yamada M. Percutaneous radiofrequency ablation for hepatocellular carcinoma located in the caudate lobe of the liver. Acta Gastroenterol. Belg. 2015; 78 (3): 267-273.
24.Косырев В.Ю., Долгушин Б.И., Мартынков Д.В., Шолохов В.Н. Сравнение эффективности чрескожной радиочастотной аблации опухолей печени в зависимости от метода навигации. Пленум правления Ассоциации хирургов-гапатологов стран СНГ: материалы. М., 2013. C. 26-27.
25.Bale R., Schullian P., Schmuth M., Widmann G., Jaschke W., Weinlich G. Stereotactic radiofrequency ablation for metastatic melanoma to the liver. Cardiovasc. Intervent. Radiol. 2016; 39 (8): 1128-1135. DOI: 10.1007/s00270-016-1336-z.
26.Bale R., Schullian P., Haidu M., Widmann G. Stereotactic Radiofrequency Ablation (SRFA) of intrahepatic cholangiocellular carcinomas: a minimal invasive alternative to liver resection. Wien Med. Wochenschr. 2013; 163 (5-6): 128-131. DOI: 10.1007/s10354-013-0182-8.
27.Bale R., Widmann G., Schullian P., Haidu M., Pall G., Klaus A., Weiss H., Biebl M., Margreiter R. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur. Radiol. 2012; 22 (4): 930-937. DOI: 10.1007/s00330-011-2314-0.
28.Cazzato R.L., Garnon J., Ramamurthy N., Tsoumakidou G., Imperiale A., Namer I.J., Bachellier P., Caudrelier J., Rao P., Koch G., Gangi A. 18F-FDOPAPET/CT-Guided radiofrequency ablation of liver metastases from neuroendocrine tumours: Technical noteona preliminary experience. Cardiovasc. Intervent. Radiol. 2016; 39 (9): 1315-1321. DOI: 10.1007/s00270-016-1334-1.
29.Zhao Z., Wu J., Liu X., Liang M., Zhou X., Ouyang S., Yao J., Wang J., Luo B. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018; 421: 73-81. DOI: 10.1016/j.canlet.2018.02.024.
30.Vincenzi B., Di Maio M., Silletta M., D’Onofrio L., Spoto C., Piccirillo M.C., Daniele G., Comito F., Maci E., Bronte G., Russo A., Santini D., Perrone F., Tonini G. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with locoregional therapies: a literature-based meta-analysis. PLoS One. 2015; 10 (7): e0133488. DOI: 10.1371/journal.pone.
31.Samim M., Molenaar I.Q., Seesing M.F., van Rossum P.S., van den Bosch M.A., Ruers T.J., Borel Rinkes I.H., van Hillegersberg R., Lam M.G., Verkooijen H.M. The diagnostic performance of 18F-FDG PET/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases: A systematic review and meta-analysis. Surg. Oncol. 2017; 26 (1): 37-45. DOI: 10.1016/j.suronc.2016.12.006.
32.Huang Y.Z., Zhou S.C., Zhou H., Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013; 60 (125): 1131-1135. DOI: 10.5754/hge121142.
33.Yi P.S., Huang M., Zhang M., Xu L., Xu M.Q. Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma. Am. Surg. 2018; 84 (2): 282-288.
34.Guo W., He X., Li Z., Li Y. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on survival outcome of early hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology. 2015; 62 (139): 710-714.
35.Yang W., Yan K., Goldberg S.N., Ahmed M., Lee J.C., Wu W., Zhang Z.Y., Wang S., Chen M.H. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J. Gastroenterol. 2016; 22 (10): 2993-3005. DOI: 10.3748/wjg.v22.i10.2993.
36.Zhou Y., Zhao Y., Li B., Xu D., Yin Z., Xie F., Yang J. Metaanalysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology. 2010; 10: 78. DOI: 10.1186/1471-230X-10-78.
37.Feng Q., Chi Y., Liu Y., Zhang L., Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J. Cancer Res. Clin. Oncol. 2015; 141 (1): 1-9. DOI: 10.1007/s00432-014-1708-1.
38.Wang Y., Luo Q., Li Y., Deng S., Wei S., Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014; 9 (1): e84484. DOI: 10.1371/journal.pone.0084484.
39.Qi X., Tang Y., An D., Bai M., Shi X., Wang J., Han G., Fan D. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J. Clin. Gastroenterol. 2014; 48 (5): 450-457. DOI: 10.1097/MCG.0000000000000008.
40.Lan T., Chang L., Rahmathullah M.N., Wu L., Yuan Y.F. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016; 95 (15): e3185. DOI: 10.1097/MD.0000000000003185.
41.Yang B., Zan R.Y., Wang S.Y., Li X.L., Wei M.L., Guo W.H., You X., Li J., Liao Z.Y. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J. Surg. Oncol. 2015; 13: 96. DOI: 10.1186/s12957-015-0516-7.
42.Chen S., Peng Z., Xiao H., Lin M., Chen Z., Jiang C., Hu W., Xie X., Liu L., Peng B., Kuang M. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int. J. Hyperthermia. 2017: 1-9. DOI: 10.1080/02656736.2017.1387941.
43.Porrett P.M., Peterman H., Rosen M., Sonnad S., Soulen M., Markmann J.F., Shaked A., Furth E., Reddy K.R., Olthoff K. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD Era. Liver Transplantation. 2006; 12 (4): 665-673.
44.NCCN (National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology). https://www.nccn.org/professionals/physician_gls/default.aspx.
45.Llovet J.M., Ducreux M., Lencioni R., Di Bisceglie A.M., Galle P.R., Dufour J.F., Greten T.F., Raymond E., Roskams T., De Baere T., Ducreux M., Mazzaferro V., Bernardi M. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatology. 2012; 56: 908-943. DOI: 10.1016/j.jhep.2011.12.001.
46.Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Zhu A.X., Murad M.H., Marrero J.A. AASLD Guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67 (1): 358-380. DOI: 10.1002/hep.29086.
47.Chen S., Peng Z., Xiao H., Lin M., Chen Z., Jiang C., Hu W., Xie X., Liu L., Peng B., Kuang M. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int. J. Hyperthermia. 2017: 1-34.
48.Li W., Bai Y., Wu M., Shen L., Shi F., Sun X., Lin C., Chang B., Pan C., Li Z., Wu P. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: Propensity score matching analysis. Oncotarget. 2017; 8 (32): 52132-52141. DOI: 10.18632/oncotarget.10383.
49.Yasumoto T., Uemoto K., Yamada K., Koh H., Yamazaki M., Masai N., Tatsumi D., Oh R. Radiofrequency ablation under computed tomography during arterial portography for hypovascular liver metastases from advanced pancreatic cancer. Gan To Kagaku Ryoho. 2018; 45 (2): 371-373.
50.Azevedo A., Falsarella P., Rocha R., Rahal A., Garcia R. Percutaneous cholecystostomy and hydrodissection in radiofrequency ablation of liver subcapsular leiomyosarcoma metastasis adjacent to the gallbladder: Protective effect. J. Radiol. Case Rep. 2016; 10 (10): 24-32. DOI: 10.3941/jrcr.v10i10.2677.
51.Liu B., Huang G., Jiang C., Xu M., Zhuang B., Lin M., Tian W., Xie X., Kuang M., Xie X. Ultrasound-guided percutaneous radiofrequency ablation of liver metastasis from ovarian cancer: A single-center initial experience. Int. J. Gynecol. Cancer. 2017; 27 (6): 1261-1267. DOI: 10.1097/IGC.0000000000000939.
52.Lee J.W., Choi M.H., Lee Y.J., Ali B., Yoo H.M., Song K.Y., Park C.H. Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection. BMC Cancer. 2017; 17 (1): 185. DOI: 10.1186/s12885-017-3156-1.
53.Abbas H., Erridge S., Sodergren M.H., Papoulas M., Nawaz A., Menon K., Heaton N.D., Prachalias A.A., Srinivasan P. Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. Int. J. Surg. 2017; 44: 152-159. DOI: 10.1016/j.ijsu.2017.06.049.
54.Du S., Ni J., Weng L., Ma F., Li S., Wang W., Sang X., Lu X., Zhong S., Mao Y. Locoregional treatment improves the outcomeof liver metastases from grade 3 gastroenteropancreatic neuroendocrine tumors. Medicine (Baltimore). 2015; 94 (34): e1429. DOI: 10.1097/MD.0000000000001429.
55.Mulier S., Ni Y., Jamart J., Ruers T., Marchal G., Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann. Surg. 2005; 242 (2): 158-171.
56.Elias D., Goéré D., Leroux G., Dromain C., Leboulleux S., de Baere T., Ducreux M., Baudin E. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur. J. Surg. Oncol. 2009; 35 (10): 1092-1097. DOI: 10.1016/j.ejso.2009.02.017.
57.Akyildiz H.Y., Mitchell J., Milas M., Siperstein A., Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: Long-term follow-up. Surgery. 2010; 148 (6): 1288-1293. DOI: 10.1016/j.surg.2010.09.014.
58.Mazzaglia P.J., Berber E., Milas M., Siperstein A.E. Laparoscopic raziofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007; 142 (1): 10-19.
59.Ruers T., Punt C., Van Coevorden F., Pierie J.P., Borel-Rinkes I., Ledermann J.A., Poston G., Bechstein W., Lentz M.A., Mauer M., Van Cutsem E., Lutz M.P., Nordlinger B. Radio frequency ablation combined with systemic treatment versus systemic treatment alone in patients with nonresectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann. Oncol. 2012; 23 (10): 2619-2626. DOI: 10.1093/annonc/mds053.
60.Hur H., Ko Y.T., Min B.S., Kim K.S., Choi J.S., Sohn S.K., Cho C.H., Ko H.K., Lee J.T., Kim N.K. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am. J. Surg. 2009; 197 (6): 728-736. DOI: 10.1016/j.amjsurg.2008.04.013.
61.Guo Y.L., Tong Z.H., Xu X., Zhao Y., Liu J.W., Wang H.G., Dong G.L. Colorectal resection combined with simultaneous radiofrequency ablation in the treatment of synchronous colorectal liver metastases: a retrospective analysis. Zhonghua Yi Xue Za Zhi. 2017; 97 (12): 925-928. DOI: 10.3760/cma.j.issn.0376-2491.2017.12.010.
62.Lee B.C., Lee H.G., Park I.J., Kim S.Y., Kim K.H., Lee J.H., Kim C.W., Lee J.L., Yoon Y.S., Lim S.B., Yu C.S., Kim J.C. The role of radiofrequency ablation for treatment of metachronous isolated hepatic metastasis from colorectal cancer. Medicine (Baltimore). 2016; 95 (39): e4999. DOI: 10.1097/MD.0000000000004999.
63.Meijerink M.R. COLLISION Trial - Colorectal Liver Metastases: Surgeryvs Thermal Ablation. ClinicalTrials.gov NCT03088150. https://clinicaltrials.gov/ct2/show/NCT03088150.
64.Jianmin X. Study comparing radiofrequency ablation plus chemotherapy and chemotherapy alone in patients with unresectable CRLM. ClinicalTrials.gov NCT03127072. https://clinicaltrials.gov/ct2/show/NCT03127072.
65.Kim W.W., Kim K.H., Kim S.H., Kim J.S., Park S.J., Kim K.H., Choi C.S., Choi Y.K. Comparison of hepatic resection and radiofrequency ablation for the treatment of colorectal liver metastasis. Indian J. Surg. 2015; 77 (Suppl 3): 1126-1130. DOI: 10.1007/s12262-015-1211-1.
66.Imai K., Allard M.A., Benitez C., Vibert E., Sa Cunha A., Cherqui D., Castaing D., Baba H., Adam R. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br. J. Surg. 2017; 104 (5): 570-579. DOI: 10.1002/bjs.10447.
67.Ni J.Y., Liu S.S., Xu L.F., Sun H.L., Chen Y.T. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J. Gastroenterol. 2013; 19 (24): 3872-3882. DOI: 10.3748/wjg.v19.i24.3872.
68.Liu H., Wang Z.G., Fu S.Y., Li A.J., Pan Z.Y., Zhou W.P., Lau W.Y., Wu M.C. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br. J. Surg. 2016; 103 (4): 348-356. DOI: 10.1002/bjs.10061.
69.Yi P.S., Huang M., Zhang M., Xu L., Xu M.Q. Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma. Am. Surg. 2018; 84 (2): 282-288.
70.Guo W., He X., Li Z., Li Y. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on survival outcome of early hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology. 2015; 62 (139): 710-714.
71.Pompili M., Saviano A., de Matthaeis N., Cucchetti A., Ardito F., Federico B., Brunello F., Pinna A.D., Giorgio A., Giulini S.M., De Sio I., Torzilli G., Fornari F., Capussotti L., Guglielmi A., Piscaglia F., Aldrighetti L., Caturelli E., Calise F., Nuzzo G., Rapaccini G.L., Giuliante F. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma 3 cm. Results of a multicenter Italian survey. J. Hepatol. 2013; 59 (1): 89-97. DOI: 10.1016/j.jhep.2013.03.009.
72.Wu L.V., Chen C.Y., Liu C.J., Chen M.Y., Liu P.C., Liu P.F., Seror O., Lee I.L., Lin S.M. Multipolar radiofrequency ablation with non-touch technique for hepatocellular carcinoma ≤3 cm: A preliminary report. Adv. Dig. Med. 2014; 1 (3): 80-85.
73.Hocquelet A., Aubé C., Rode A., Cartier V., Sutter O., Manichon A.F., Boursier J., N''kontchou G., Merle P., Blanc J.F., Trillaud H., Seror O. Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. J. Hepatol. 2017; 66 (1): 67-74. DOI: 10.1016/j.jhep.2016.07.010.

Radiofrequency thermal destruction in current treatment of liver malignancies. Literature review

Dolgushin B. I., Kosyrev V. Y., Virshke E. R., Sholokhov V. N., Martynkov D. V.

Radiofrequency thermal destruction (thermoablation) remains one of the most popular methods of local destruction of liver tumors. There are perennial international experience in oncology, numerous trials and practical issues are rarely discussed. However, there are still strategic questions: when, to whom, in what cases. In fact, specialists recognizing effective impact do not always sure when thermoablation potential will be realized as much as possible. In this review the authors summarized world experience of liver malignancies thermoablation and tried to identify key positions in determining treatment strategy using this approach. Interdisciplinary approach is an absolute priority in optimal treatment of these patients.

Keywords:
печень, злокачественное новообразование, метастазы, радиочастотная термодеструкция, абляция, liver, malignancy, metastases, radiofrequency thermodestruction, ablation

Новости   Магазин   Журналы   Контакты   Правила   Доставка   О компании  
ООО Издательский дом ВИДАР-М, 2016